Moreover, IG1 could be responsive for myeloid-targeted therapies as those based on CXCR2 (C-X-C motif chemokine receptor 2) and CSFR (colony-stimulating factor receptor) inhibitors to deplete or reprogram tumor-associated neutrophils and M2 macrophages. This evidence concerns the gene CXCR2 and neoplasm.